Hot topics

Here you'll find resources we've developed in response to a number of queries received around a given topic.

As these resources have not been through the full QA process and are designed as an information resource for you to use locally to support decision making, we ask that you do not add these resources to public facing web pages.

Alkindi® Hydrocortisone

Alkindi® has recently been launched as a licenced hydrocortisone for replacement therapy of adrenal insufficiency in children and adolescents (from birth to <18 years old).

The document below summarises some of the associated issues, problems and risks.

Alkindi® - September 2019.pdf

GLP-1 Mimetic Quantities

Lowering the inhaler carbon footprint

The NHS has committed to lowering the inhaler carbon footprint.

This resource provides you with practical steps towards lowering the inhaler carbon footprint in addition to suggested switches which are cost saving or cost neutral.

Attachment 1 provides a comparison of inhalers by device type, indications and age range, indicative carbon footprint and costs. The data will be of assistance when considering lower carbon footprint inhaler alternatives to pMDIs.

An impact tool will be available soon which will allow users to view the impact of any inhaler switches they are considering in terms of cost and carbon footprint.

Lowering the Inhaler carbon footprint - February 2020.pdf

Attachment 1. Inhaler comparisons including indicative carbon footprint 2.0.xlsx

Iopidine® (apraclonidine) eye drops

We have received reports that some GP practices are adding Iopidine® eye drops onto repeat prescription despite the maximum treatment duration recommended is one month.

There has been an increase in the use of the preservative free higher strength Iopidine® 1% eye drops compared to the lower strength Iopidine® 0.5% eye drops in England. This raises potential patient safety concerns if the higher strength formulation is being used as a preservative free alternative to Iopidine® 0.5% eye drops.

We have summarised the issues and suggest medicine optimisation solutions to improve patient safety and avoid unnecessary costs.

Iopidine® (apraclonidine) eye drops - October 2019.pdf

Melatonin preparations

PrescQIPP has received numerous queries on the newly licensed melatonin products. A PrescQIPP bulletin is in production which will cover these in more detail. We thought a quick summary in the interim would be helpful.

Newly licensed melatonin preparation - 12-07-19.pdf

Namuscla (mexiletine)

A licensed version of mexiletine, Namuscla® 167mg capsules was launched earlier this year.

There is likely to be a significant cost pressure in primary and secondary care if this is introduced without consideration given to medicine optimisation.

We have summarised the issues and suggest medicine optimisation solutions to reduce cost pressures.

Namuscla (mexiletine) - August 2019.pdf